Page 162 - Read Online

Few reports are available to date about the predictive Acknowledgments
value of electrophysiological findings in NSAS. We thank Dr. Angela Vincent and Dr. Raffaele Iorio for
[60]
Identifying specific EEG pathological patterns may performing diagnostic laboratory workup.
help not only in distinguishing the different forms,
but also in recognizing them at an initial stage, with Financial support and sponsorship
the aim of administering an early treatment. Moreover Nil.
MRI-patterns, despite providing a supportive feature in
the diagnostic flow-chart orientation, are often quite a Conflicts of interest
[43]
specific, and thereby usually insufficient, if alone, There are no conflicts of interest.
to get specific NSAS distinguishable from each other, REFERENCES
especially at clinical onset.
1. Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous
Correlations between electrophysiological and system neuronal surface antibody associated syndromes: review
neuroradiological data are then mandatory, but and guidelines for recognition. J Neurol Neurosurg Psychiatry
2012;83:638-45.
remain partly unexplored. Modern neuroradiological 2. Vernino S, Geschwind M, Boeve B. Autoimmune encephalopathies.
techniques are now increasingly available and could Neurologist 2007;13:140-7.
be useful to better understand pathophysiological 3. Melzer N, Meuth SG, Wiendl H. Paraneoplastic and non-
paraneoplastic autoimmunity to neurons in the central nervous
mechanism and disclose predictive outcome data in system. J Neurol 2013;260:1215-33.
different NSAS. [43] 4. Lancaster E, Dalmau J. Neuronal autoantigens-pathogenesis,
associated disorders and antibody testing. Nat Rev Neurol
2012;8:380-90.
Moreover, no consensus is obtained to date about the 5. Alavi S. Paraneoplastic neurologic syndromes in children: a review
sensibility and specificity of serum vs. CSF testing. 6. article. Iran J Child Neurol 2013;7:6-14.
Hacohen Y1, Wright S, Waters P, Agrawal S, Carr L, Cross H, De
Although a study performed by Gresa-Arribas et al. Sousa C, Devile C, Fallon P, Gupta R, Hedderly T, Hughes E, Kerr
[61]
in 2014 demonstrated the higher CSF testing reliability T, Lascelles K, Lin JP, Philip S, Pohl K, Prabahkar P, Smith M,
in NMDA-R encephalitis, consensual data lack on the Williams R, Clarke A, Hemingway C, Wassmer E, Vincent A, Lim
MJ. Paediatric autoimmune encephalopathies: clinical features,
others NSAS. Moreover, the same work stressed out laboratory investigations and outcomes in patients with or without
a positive correlation between the antibody titer and antibodies to known central nervous system autoantigens. J Neurol
Neurosurg Psychiatry 2013;84:748-55.
the risk of relapse, but no predictive threshold value 7. Dalmau J, Bataller L. Limbic encephalitis: the new cell membrane
has been established to help in deciding to resort to a antigens and a proposal of clinical-immunological classification
retreatment or a chronic immunotherapy. with therapeutic implications. Neurologia 2007;22:526-37 (in
Spanish).
8. Suleiman J, Wright S, Gill D, Brilot F, Waters P, Peacock K, Procopis
Finally, concerning the therapeutic approach, P, Nibber A, Vincent A, Dale RC, Lang B. Autoantibodies to neuronal
strategies tailored to the individual syndrome should antigens in children with new-onset seizures classified according to
the revised ILAE organization of seizures and epilepsies. Epilepsia
be outlined, considering a less aggressive approach for 2013;54:2091-100.
those with a usually better outcome, such as NMDA-R 9. Suleiman J, Dale RC. The recognition and treatment of autoimmune
epilepsy in children. Dev Med Child Neurol 2015;57:431-40.
encephalitis. [46,47] This must be done by taking into 10. Suleiman J, Brilot F, Lang B, Vincent A, Dale RC. Autoimmune
account the possible side effects of immunotherapic epilepsy in children: case series and proposed guidelines for
identification. Epilepsia 2013;54:1036-45.
drugs and a “risks vs. benefits” assessment per single 11. Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A,
patient. [62] Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing
LH, Dichter MA, Rosenfeld MR, Lynch DR. Paraneoplastic anti-N-
CONCLUSION methyl-D-aspartate receptor encephalitis associated with ovarian
teratoma. Ann Neurol 2007;61:25-36.
12. Wright S, Hacohen Y, Jacobson L, Agrawal S, Gupta R, Philip S,
In children NSAS clinical picture is heterogeneous, Smith M, Lim M, Wassmer E, Vincent A. N-methyl-D-aspartate
often overlapping and still poorly outlined. Anyhow, receptor antibody-mediated neurological disease: results of a UK-
based surveillance study in children. Arch Dis Child 2015;100:521-
the recognition of some characteristic clinical 6.
features are sometimes possible, and can help the 13. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR,
diagnostic approach with the aim to start a proper Balice-Gordon R. Clinical experience and laboratory investigations
in patients with anti-NMDAR encephalitis. Lancet Neurol
and early treatment. Nevertheless, further studies on 2011;10:63-74.
larger prospective pediatric cohorts and randomized 14. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S,
Campen CJ, Moss H, Peter N, Gleichman AJ, Glaser CA, Lynch
treatment trials are required in order to assess the need DR, Rosenfeld MR, Dalmau J. Anti-N-methyl-D-aspartate receptor
to tailor more or less aggressive treatments according (NMDAR) encephalitis in children and adolescents. Ann Neurol
2009;66:11-8.
to long term outcome findings and prognostic factors 15. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL,
in different NSAS. Morgan D, Cunningham R, Zuckerman M, Mutton KJ, Solomon
Neuroimmunol Neuroinflammation | Volume 3 | July 8, 2016 153